Patients with hepatocellular carcinoma who received lenvatinib between October 1, 2018 and September 30, 2020.
Patients enrolled in the "Multicenter Study of Factors Contributing to the Efficacy and Survival of Lenvatinib in Hepatocellular Carcinoma".
Patients who have arbitrarily stored serum before and after treatment.
主たる除外基準 / Exclusion Criteria
研究責任者および研究分担者が本研究の参加が不適と考えられた患者
Patients who are considered unsuitable for participation in this study by the principal investigator and sub-investigators
年齢下限 / Age Minimum
20歳 以上
20age old over
年齢上限 / Age Maximum
上限なし
No limit
性別 / Gender
男性・女性
Both
中止基準
対象疾患名 / Health Condition(s) or Problem(s) Studied
切除不能な肝細胞癌
Unresectable hepatocellular carcinoma
対象疾患コード / Code
D006528
対象疾患キーワード / Keyword
肝細胞癌
Hepatocellular Carcinomas
介入の有無
なし
介入の内容 / Intervention(s)
介入コード / Code
介入キーワード /Keyword
主たる評価項目 / Primary Outcome(s)
レンバチニブが投与された肝細胞癌患者を対象に、初回投与時のNOS活性と投与後のNOS活性の比較検討
Comparison of NOS activity at the time of initial administration and after administration in patients with hepatocellular carcinoma treated with lenvatinib
Effect of NOS activity at first dose on response rate, overall survival, progression-free survival, Time To Progression, Time to treatment failure, and incidence of adverse effects after lenvatinib treatment